Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
The new site enables end-to-end production of viral vector gene therapies
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Subscribe To Our Newsletter & Stay Updated
